The Global Health Body Issues Warning Over Critical Scarcity of Weight-Loss Jabs

Fewer than 10% of people who could benefit from weight-loss injections like Wegovy are able to get them, caution the World Health Organization as it publishes its initial advice on the drugs.

Given in excess of 1,000,000,000 individuals worldwide now obese, it is calling for broader and more equitable access to GLP-1 medication.

Per forecasts, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.

"The new guidance acknowledges that obesity is a long-term condition that can be addressed with thorough and continuous treatment," said WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and supply-chain constraints are significant barriers to universal availability to the injections that can help people shift significant body mass, explains the organization.

Skinny Jab Shortage

Even under the current most favorable scenario, the production of such drugs would only suffice for around 100 million people – less than 10% of those who need them, as stated by the health organization.

The guideline urges countries and companies to increase availability, via approaches like patent sharing.

Exclusive production rights on a key compound – the primary component of the drug Wegovy – is set to lapse in a number of countries in 2026.

How Weight-Loss Injections Function

GLP-1 drugs replicate a biological compound to delay gastric emptying, reduce hunger and boost satiety so people eat less.

Patients commonly see weight reduction after several weeks of beginning the weekly injections.

Evidence suggests users may see weight return after a year of stopping the treatment, because their usual appetite return.

Being overweight or obese raises your likelihood for contracting diseases, including diabetes, cardiovascular issues, stroke, and certain malignancies.

Obesity impacts individuals in all nations and was linked to millions of deaths worldwide in 2024, per the health agency.